Aurinia's R&D Spending Doubles To $16.6 Million As Tax Bill Flattens Profit
Pre-tax income rose to $38.7 million, but net income held at $31.7 million as taxes returned and buybacks stopped.
Aurinia Pharmaceuticals, which develops therapies for autoimmune diseases, spent $16.6 million on research and development in the third quarter, up from $8.4 million a year earlier, according to its 10-Q filed Friday. Income taxes rose to $7.0 million from $0.4 million, leaving net income at $31.7 million against $31.6 million.
Tax ate the pre-tax gain
Pre-tax income climbed to $38.7 million from $32.0 million, but the jump in income tax expense absorbed nearly all of it. Diluted earnings per share was $0.23, the same as a year ago, the company's earnings release shows.
Last year Aurinia used unrecognized deferred tax assets to cut its tax bill. It recognized all of them in the fourth quarter of 2025, so none were available to offset 2026 taxes. The effective tax rate was 18.1% for the quarter and 21.3% for nine months, against 1.3% and 2.6% a year earlier, and the company says it is now comparable to the statutory rate.
Over nine months, net income rose to $103.5 million from $76.4 million. Revenue was $83.7 million in the quarter, up 14%, with LUPKYNIS net product sales of $79.4 million, up 12%.
R&D climbs, buybacks stop
Nine-month R&D reached $37.1 million against $21.6 million. Second-quarter R&D was $13.1 million, per the prior 10-Q, so spending rose again. The company attributes the increase to more R&D employees, clinical manufacturing and supply, and other development costs, and says it expects R&D to keep rising as development progresses.
Stock pay inside R&D rose to $2.5 million from $327,000. In SG&A it fell to $3.4 million from $5.4 million; for nine months, the filing ties the decline to reversed expense on forfeited awards of terminated employees.
Aurinia repurchased no shares in the quarter, compared with 1.1 million shares for $8.8 million a year earlier. It bought 5.0 million shares for $74.9 million over the nine months.
Cash pile and patent fights
Aurinia sells LUPKYNIS, an oral lupus nephritis therapy, in the U.S. and through partner Otsuka elsewhere. It also bought Kezar Life Sciences on May 11, accounted for as an asset acquisition. Cash and investments stood at $486.9 million on September 30, against $398.0 million at the end of 2025.
The company raised its 2026 total revenue guidance to $325 million to $330 million, from $315 million to $325 million, and narrowed net product sales guidance to $310 million to $315 million.
On August 17 Aurinia settled with generic maker Teva, which may launch a generic voclosporin no earlier than December 7, 2036, unless certain contingencies occur, and only with FDA approval. Suits continue against DifGen, Dr. Reddy's, Hikma, Lotus, Sandoz and Zydus in New Jersey federal court.
The company says it expects R&D spending to keep increasing, with the buyback authorization still in place after a quarter of no purchases.
Sources
- 10-Q Filing — Aurinia Pharmaceuticals (AUPH) — SEC EDGAR
- 10-Q Filing — Aurinia Pharmaceuticals (AUPH), Q2 FY2026 filed 2026-08-06 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, exhibit991_q32026earningsr.htm) — Aurinia Pharmaceuticals, filed 2026-10-30 — SEC EDGAR
- Aurinia Pharma GAAP EPS of $0.23 beats by $0.01, revenue of $83.7M beats by $0.09M (AUPH:NASDAQ) | Seeking Alpha — seekingalpha.com
- Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline — Yahoo Finance
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress | Financial Post — financialpost.com
- Aurinia Pharmaceuticals Inc. et al v. Tidmarsh — law360.com